Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,220.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target increased by research analysts at Barclays from $1,200.00 to $1,220.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price target points to a potential upside of 12.61% from the stock’s previous close.

A number of other equities analysts have also weighed in on REGN. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Piper Sandler boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,078.82.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of REGN stock traded down $9.79 during trading hours on Friday, hitting $1,083.35. 151,512 shares of the company’s stock traded hands, compared to its average volume of 467,167. The stock’s fifty day simple moving average is $1,041.48 and its two-hundred day simple moving average is $981.44. Regeneron Pharmaceuticals has a 12-month low of $759.15 and a 12-month high of $1,113.38. The stock has a market cap of $119.37 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 2.31 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. On average, analysts expect that Regeneron Pharmaceuticals will post 37.38 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The disclosure for this sale can be found here. Insiders have sold 65,074 shares of company stock worth $64,546,123 over the last 90 days. 7.48% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $932,571,000. Global Assets Advisory LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $339,594,000. Capital International Investors raised its position in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. First Trust Advisors LP raised its position in Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares during the last quarter. Finally, abrdn plc raised its position in Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after buying an additional 186,215 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.